Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Comparison to a Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease

• Status: Completed
• Trial end date: 1969-12-31

Summary

New perceptions about handling and patient satisfaction of the everyday use of Berodual® Respimat® compared to a powder inhaler in patients with chronic obstructive lung disease (COLD). Moreover, further knowledge should be attained about the tolerability of Berodual® Respimat®

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Fenoterol; Fenoterol, ipratropium drug combination; Ipratropium